Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA “Unable” To Act On Hylenex By User Fee Deadline

Sep 26 2005

• By Mary Jo Laffler

Related Content

Sandoz Sues FDA For Inaction On Omnitrope NDA

Sep 14 2005

Vitrase Gains New Molecular Entity Status Due To Lack Of Characterization

Oct 28 2004

Baxter/Halozyme Hyaluronidase Enhanze SC Could See Approval By September

Apr 25 2005

Amphastar's Spreading Agent Amphadase Clears FDA

Oct 27 2004

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window